Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 15/20 | 0.72 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 7/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.65 |
| ▸ | HTT | P42858 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.60 |
| ▸ | HPGD | P15428 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | PPARG | P37231 | 3/20 | 0.60 |
| ▸ | NCOA2 | Q15596 | 3/20 | 0.60 |
| ▸ | NCOA1 | Q15788 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469852 | 0.81 | MAPT (0.67) | MAPTRXFP1MEN1KMT2AALDH1A1 | |
| SCHEMBL6467333 | 0.75 | MAPT (1.00) | MAPTRXFP1MEN1KMT2AALDH1A1 | |
| SCHEMBL12561620 | 0.75 | MAPT (0.53) | MAPTRXFP1MEN1KMT2AALDH1A1 | |
| SCHEMBL6466697 | 0.74 | MAPT (0.75) | MAPTRXFP1MEN1KMT2AALDH1A1 | |
| SCHEMBL1590727 | 0.74 | KCNH2 (0.50) | MAPTRXFP1MEN1KMT2AALDH1A1 | |
| SCHEMBL6468505 | 0.73 | MAPT (0.73) | MAPTRXFP1MEN1KMT2AALDH1A1 | |
| SCHEMBL6469690 | 0.73 | MAPT (1.00) | MAPTRXFP1MEN1KMT2AALDH1A1 | |
| SCHEMBL12103576 | 0.73 | SMPD3 (0.69) | MAPTRXFP1MEN1KMT2AALDH1A1 | |
| SCHEMBL244059 | 0.73 | SMPD3 (0.80) | MAPTRXFP1MEN1KMT2AALDH1A1 | |
| SCHEMBL6468972 | 0.73 | MAPK13 (0.74) | MAPTTP53MAPK13GCGRMAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | AXXIMA PHARMACEUTICAL AG. (DE) | 2005-09-15 | — | — | US | claimed |
| EP-1532118-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2005-05-25 | — | — | EP | claimed |
| WO-2004005264-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-01-15 | — | — | WO | claimed |
| US-20240000821-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | UNIV JOHNS HOPKINS (US) | 2024-01-04 | — | — | US | disclosed |
| US-20200078387-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | THE JOHNS HOPKINS UNIVERSITY | 2020-03-12 | — | — | US | disclosed |
| WO-2018112342-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | AXXIMA PHARMACEUTICAL AG. (DE) | 2005-09-15 | — | — | US | disclosed |
| EP-1532118-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004005264-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | CSNK1G1, CSNK1E, CSNK1D | MAPT 1480/4885RXFP1 3972/4885MEN1 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.